Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology

Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Meth...

Full description

Bibliographic Details
Main Authors: Aayla K. Jamil, MBBS, MPH, Amit Alam, MD, Ronnie M. Youssef, MD, Joost Felius, PhD, Johanna S. van Zyl, PhD, Robert L. Gottlieb, MD, PhD
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S254245482100076X
id doaj-834bda882b3a4bc087eb02eefe8e7040
record_format Article
spelling doaj-834bda882b3a4bc087eb02eefe8e70402021-08-26T04:35:39ZengElsevierMayo Clinic Proceedings: Innovations, Quality & Outcomes2542-45482021-10-0155827834Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic PathologyAayla K. Jamil, MBBS, MPH0Amit Alam, MD1Ronnie M. Youssef, MD2Joost Felius, PhD3Johanna S. van Zyl, PhD4Robert L. Gottlieb, MD, PhD5Baylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TX; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TXCollege of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TX; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX; Department of Internal Medicine, TCU and UNTHSC School of Medicine, Fort Worth, TX; Correspondence: Address to Robert L. Gottlieb, MD, PhD, Center for Advanced Heart and Lung Disease, Baylor Scott & White Health, 3410 Worth St, Suite 250, Dallas, TX 75246.Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Methods: We retrospectively reviewed patients within our health care system from March 15, 2020, through May 31, 2020, who had a diagnosis of pneumothorax or pneumomediastinum during hospitalization for confirmed COVID-19 infection with attention to timing of pneumothorax and pneumomediastinum; presence, laterality, and placement, or attempts at central lines; and presence of mechanical ventilation before the event. Results: We report clinical data and outcomes from 9 hospitalized patients with COVID-19 who developed pneumothorax and/or pneumomediastinum among more than 1200 hospitalized patients admitted within our hospital system early in the pandemic. Many events were inexplicable by iatrogenic needle injury, including 1 spontaneous case without central line access or mechanical ventilation. One occurred before central line placement, 2 in patients with only a peripherally inserted central line, and 1 contralateral to a classic central line. Three of these 9 patients died of complications of COVID-19 during their hospital stay. Conclusion: With COVID-19 affecting the peripheral lung pneumocytes, patients are vulnerable to develop pneumothorax or pneumomediastinum irrespective of their central line access site. We hypothesize that COVID-19 hyperinflammation, coupled with the viral tropism that includes avid involvement of peripheral lung pneumocytes, induces a predisposition to peripheral bronchoalveolar communication and consequent viral hyperinflammatory-triggered pneumothorax and pneumomediastinum.http://www.sciencedirect.com/science/article/pii/S254245482100076X
collection DOAJ
language English
format Article
sources DOAJ
author Aayla K. Jamil, MBBS, MPH
Amit Alam, MD
Ronnie M. Youssef, MD
Joost Felius, PhD
Johanna S. van Zyl, PhD
Robert L. Gottlieb, MD, PhD
spellingShingle Aayla K. Jamil, MBBS, MPH
Amit Alam, MD
Ronnie M. Youssef, MD
Joost Felius, PhD
Johanna S. van Zyl, PhD
Robert L. Gottlieb, MD, PhD
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
author_facet Aayla K. Jamil, MBBS, MPH
Amit Alam, MD
Ronnie M. Youssef, MD
Joost Felius, PhD
Johanna S. van Zyl, PhD
Robert L. Gottlieb, MD, PhD
author_sort Aayla K. Jamil, MBBS, MPH
title Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
title_short Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
title_full Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
title_fullStr Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
title_full_unstemmed Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
title_sort pneumothorax and pneumomediastinum in covid-19 suggest a pneumocystic pathology
publisher Elsevier
series Mayo Clinic Proceedings: Innovations, Quality & Outcomes
issn 2542-4548
publishDate 2021-10-01
description Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Methods: We retrospectively reviewed patients within our health care system from March 15, 2020, through May 31, 2020, who had a diagnosis of pneumothorax or pneumomediastinum during hospitalization for confirmed COVID-19 infection with attention to timing of pneumothorax and pneumomediastinum; presence, laterality, and placement, or attempts at central lines; and presence of mechanical ventilation before the event. Results: We report clinical data and outcomes from 9 hospitalized patients with COVID-19 who developed pneumothorax and/or pneumomediastinum among more than 1200 hospitalized patients admitted within our hospital system early in the pandemic. Many events were inexplicable by iatrogenic needle injury, including 1 spontaneous case without central line access or mechanical ventilation. One occurred before central line placement, 2 in patients with only a peripherally inserted central line, and 1 contralateral to a classic central line. Three of these 9 patients died of complications of COVID-19 during their hospital stay. Conclusion: With COVID-19 affecting the peripheral lung pneumocytes, patients are vulnerable to develop pneumothorax or pneumomediastinum irrespective of their central line access site. We hypothesize that COVID-19 hyperinflammation, coupled with the viral tropism that includes avid involvement of peripheral lung pneumocytes, induces a predisposition to peripheral bronchoalveolar communication and consequent viral hyperinflammatory-triggered pneumothorax and pneumomediastinum.
url http://www.sciencedirect.com/science/article/pii/S254245482100076X
work_keys_str_mv AT aaylakjamilmbbsmph pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
AT amitalammd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
AT ronniemyoussefmd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
AT joostfeliusphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
AT johannasvanzylphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
AT robertlgottliebmdphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology
_version_ 1721196007545372672